GFP Stable Cell Line-HCT-116

Colorectal cancer (CRC) is a prevalent cancer worldwide, but the role and mechanisms of ABL1 (c-Abl), a non-receptor tyrosine kinase, in CRC are not fully understood. Researchers investigated the role of ABL1 in CRC using GFP Stable Cell Line-HCT-116. Through analysis of patient samples, CRC cell lines, and mouse models, they found that ABL1 expression was associated with CRC progression. Depletion of ABL1 inhibited CRC cell proliferation and induced apoptosis in vitro and in vivo. Ingenuity pathway analysis revealed ABL1's involvement in regulating TGF-β1 via the IRS1/PI3K/AKT pathway in CRC. These findings highlight ABL1 as a potential therapeutic target for CRC treatment.

Figure 1. Researchers used GFP Stable Cell Line-HCT-116 to study TGF-β1's role in PI3K/AKT pathway regulation. Knockdown of TGF-β1 decreased GFP fluorescence, confirming successful targeting. Western blot analysis revealed suppressed pathway activity post-TGF-β1 knockdown, offering insights into cancer signaling. Conversely, PPP3CA knockdown showed no significant effects on GFP fluorescence or pathway activity. This model facilitates research on TGF-β1-mediated signaling in cancer cells. (Liu Y, et al., 2020)